Document is current
Any future updates will be listed below
-
Authors
Sakata, Hiroyuki
Takayama, Yuya
Iwasaki, Yuna
Uchida, Hiroyuki
Nishimoto, Satoshi
Togo, Osamu
-
Funding
Funding for this research was provided by:
Nxera Pharma Japan Co., Ltd.
- License Information
-
More Information
Article History
Received: 26 August 2025
Revised: 30 January 2026
Accepted: 18 March 2026
First Online: 31 March 2026
Declarations
:
: This post-marketing drug use-results surveillance was conducted in accordance with the Declaration of Helsinki and in compliance with the Good Post-marketing Study Practice Ordinance issued by the Japanese Ministry of Health, Labour and Welfare. Under the exemptions provided by this ordinance, institutional review board approval and informed consent are not required in Japan.
: Hiroyuki Sakata has received honoraria for lecture fees from Nxera Pharma Japan, Co., Ltd. Yuya Takayama, Yuna Iwasaki, Hiroyuki Uchida, Satoshi Nishimoto, and Osamu Togo are employees of Nxera Pharma Japan Co., Ltd., Tokyo, Japan.
